In SW1222 tumor-bearing animals (tumor volumes at treatment start: 141-248 mm3), GPA33 α-DOTA-PRIT significantly slowed tumor progression and extended survival compared with mice treated with [225Ac]Pr only (Figure 4A and 4B). Here, GPA33 is linked to neoplasm.